Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study. – Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Both donanemab and Leqembi are lab-made antibodies, administered by IV, that target one Alzheimer’s culprit, sticky amyloid buildup in the brain. And both drugs come with a serious safety concern — brain swelling or bleeding that in the Lilly study was linked to three deaths. Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Half received once-a-month infusions of donanemab and half dummy infusions for 18 months.
How much difference does that make? It means donanemab slowed patients’ worsening by about four to seven months, the JAMA report concluded. Scientists already know that patients getting any amyloid-targeted therapy need repeat brain scans to check for those side effects — a costly and time-consuming hurdle.
Another concern: More than 90% of the study’s participants were white, leaving little data about how other populations might respond, Alzheimer's specialist Jennifer Manly of Columbia University wrote in JAMA.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concernAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, according to a study of 1,700 patients. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.
Read more »
Groundbreaking new Alzheimer's drug promises to slow the diseaseThe FDA has approved a groundbreaking new Alzheimer’s drug that promises to slow the disease for patients. NBC10’s Randy Gyllenhaal has more on the benefits and the risks that patients should discuss with their doctors.
Read more »
Groundbreaking Alzheimer’s drug slows disease: A ‘new era’ for treatmentDonanemab has been linked to a 40% lower risk of progressing from mild cognitive impairment to mild dementia.
Read more »
Kimiko Glenn Says Orange Is the New Black Actors Needed Second JobsHer TikTok echoed sentiments Sean Gunn had on Netflix’s picket line Friday.
Read more »
What New York Restaurant Did the New ‘RHONY’ Cast Slam?“RHONY” is back with a new cast, new drama, and one old restaurant that the Housewives are hating on, and Bravo producers are not revealing. Naturally, we investigated.
Read more »